Logo
Picture

RedHill Biopharma @RedHillBio

RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company focused on gastrointestinal and infectious diseases RedHillbio.com Tel-Aviv Joined December 2014
  • Tweets
    744
  • Followers
    1K
  • Following
    626
  • Likes
    7
RedHillBio Profile Picture

RedHill Biopharma @RedHillBio

2 weeks ago

$RDHL announces closing of up to $19.4M private placement ($6M upfront with up to $13.4M of potential proceeds) expected to strenghten liquidity & support potential transformative revenue generating acquisitions. #RDHL PR:bit.ly/3SV36cC

RedHillBio Profile Picture

RedHill Biopharma @RedHillBio

2 weeks ago

$RDHL announces up to $19.4 million private placement - $6 million upfront with up to approximately $13.4 million of potential aggregate proceeds to support a potential strategic acquisition. #RDHL PR: bit.ly/4eQ6JsV

RedHillBio Profile Picture

RedHill Biopharma @RedHillBio

4 weeks ago

#RDHL’s #opaganib receives @FDA rare pediatric disease designation for neuroblastoma, with potential for #PriorityReviewVoucher. Adds to prior #orphandrugdesignation. $RDHL PR: bit.ly/4vCodhV

RedHillBio Profile Picture

RedHill Biopharma @RedHillBio

4 weeks ago

$RDHL has commenced recognition and enforcement proceedings in #Korea for the $11 million #NewYork #SupremeCourt final judgment in favor of #RDHL against #Kukbo. Press release: bit.ly/4ogSaBS

RedHillBio Profile Picture

RedHill Biopharma @RedHillBio

a month ago

#RDHL advancing #opaganib options for #Ebola biodefense platforms, incl. @WHO’s SOLIDARITY CORE clinical trial platform & pharma collaborations, amid rapidly evolving #Bundibugyo #EVD outbreak, which has no approved medications or vaccines. $RDHL PR: bit.ly/4fUPffW

RedHillBio Profile Picture

RedHill Biopharma @RedHillBio

2 months ago

#RDHL’s RHB-204 comparable MAP killing efficacy to RHB-104, with lower doses. Key step in RHB-204’s FDA-guided path to potential groundbreaking MAP-related approach to #Crohns. Multiple FDA designations, possible PRV and regulatory exclusivities. $RDHL PR: bit.ly/3PcoCrV

RedHillBio Profile Picture

RedHill Biopharma @RedHillBio

2 months ago

$RDHL FY2025: Tenacity, transactions & traction - transformed #Talicia business with $4M Cumberland $CPIX deal, RHB-102 deal worth up to $60M with @hyloris, positive equity at end 2025 & R&D advances in #Crohn’s, #oncology & #GLP1 GI effects. #RDHL PR: bit.ly/4e6x5Hj

RedHillBio Profile Picture

RedHill Biopharma @RedHillBio

2 months ago

New preclinical data presented @AACR #AACR2026 annual meeting shows positive effects of #RDHL’s #opaganib as potential add-on therapy in models of #neuroblastoma (#NB) and triple-negative #breastcancer (#TNBC). $RDHL PR: bit.ly/4vJ6IgZ

RedHillBio Profile Picture

RedHill Biopharma @RedHillBio

4 months ago

#RDHL announces the start of joint U.S. commercialization of #Talicia with Cumberland ($CPIX), with full sales and operational launch commencing to support accelerated market penetration and expanded reach. $RDHL PR: bit.ly/4aGi5wg

RedHillBio Profile Picture

RedHill Biopharma @RedHillBio

6 months ago

#RDHL progress for #RHB-102 (#Bekinda®) in multiple GI indications, including development via FDA 505(b)(2) route, as a once-daily pill for #GLP1 GI side effects – no. 1 reason patients stop therapy, limiting $billion GLP-1 market growth. $RDHL PR: bit.ly/4jJRz9L

RedHillBio Profile Picture

RedHill Biopharma @RedHillBio

7 months ago

#RDHL’s opaganib plus venetoclax halves number of venetoclax-resistant #CLL #cancer cells in vivo compared to control – potential as add-on therapy to $2.5B blockbuster in emerging venetoclax-resistant CLL therapeutic challenge. $RDHL PR: bit.ly/3L3GqDz @GamberaleRomina

RedHillBio Profile Picture

RedHill Biopharma @RedHillBio

7 months ago

$RDHL successfully regains compliance with the @Nasdaq stockholders’ equity requirement. #RDHL PR: bit.ly/4iqrfk0

RedHillBio Profile Picture

RedHill Biopharma @RedHillBio

8 months ago

$RDHL’s $10.5 million New York Supreme Court judgment win now final for enforcement. No further appeal permissible. 9% annual statutory interest continues to accrue on award. #RDHL PR: bit.ly/47WQgzC

RedHillBio Profile Picture

RedHill Biopharma @RedHillBio

9 months ago

$RDHL secures $4 million strategic investment & U.S. co-commercialization partnership with $CPIX (Cumberland) for a 30% stake in #RDHL’s #Talicia business & shared net revenues - set to accelerate sales growth & deliver significant efficiencies. PR: bit.ly/42QLkcS

RedHillBio Profile Picture

RedHill Biopharma @RedHillBio

9 months ago

#RDHL is deeply saddened by the loss of our dear friend & SAB member, Prof. Thomas Borody. He will be greatly missed, but his legacy lives on - 1st to formulate today’s gold standard triple therapy for #HPylori & paving the way for a potential game-changing #Crohnsdisease therapy

RedHillBio Profile Picture

RedHill Biopharma @RedHillBio

9 months ago

$RDHL signs new $1.8 million + royalties Middle East deal for #Talicia - speeds entry to new Middle East markets. #RDHL receives $0.5M guaranteed payments + minimum of $1.3M in near-term milestone payments, and net sales royalties. PR: bit.ly/4gWMyZG

RedHillBio Profile Picture

RedHill Biopharma @RedHillBio

9 months ago

$RDHL wins New York Supreme Court appeal, upholding $10 million summary judgment against Kukbo, unequivocally dismissing Kukbo’s defense and stating that RedHill had fulfilled all obligations. #RDHL PR: bit.ly/487tANM

RedHillBio Profile Picture

RedHill Biopharma @RedHillBio

10 months ago

$RDHL 1H25: Bayer-supported #opaganib prostate cancer & groundbreaking #RHB-204 Crohn’s studies advancing, #Talicia growth – numbers & territories, up to $60 million #RHB-102 to @hyloris deal, net revenue up 60% & gross profit doubled. #RDHL PR: bit.ly/4845J1p

RedHillBio Profile Picture

RedHill Biopharma @RedHillBio

11 months ago

$RDHL awarded $1.8 million in legal costs and expenses by #NewYorkSupremeCourt, in addition to RedHill’s prior $8.25 million #NewYork #SupremeCourt summary judgment win. Awards include 9% ongoing statutory interest accrual. #RDHL PR: bit.ly/4mRdcoK

RedHillBio Profile Picture

RedHill Biopharma @RedHillBio

11 months ago

#RDHL has received $1.1 million in first ex-U.S. #Talicia licensing payments. $RDHL PR: bit.ly/45mZZ11

Trends for United States

Happy 4th of July
Cape Verde
Argentina
#holoSerendipity
Cabo Verde
Parmida
Colombia
Ghana
Mount Rushmore
Melanie
Happy Fourth of July
THE AIR FINAL EPISODE
#เสน่หาวาโยตอนจบ
Amora
Taylor
Caleb
Yaxel
Vozinha
Jordan Ayew
$Pauly

You might like

Updates, news & information from the Australian Department of Health, Disability and Ageing. Email questions: enquiries@health.gov.au
Australian Dept of He...
@healthgovau
125K Followers
Powerful academics. Immersive experiences. Dedicated mentoring. Pace will get you where you want to go. Where you go is up to you. #PaceGoGetters
Pace University
@PaceUniversity
16K Followers
Breaking news and analysis for the global pharmaceutical and biotechnology industries
The Pharma Letter
@ThePharmaLetter
26K Followers
We're working to realize the promise of precision medicines. Our goal is to help patients with cancer lead better, longer lives.
Kura Oncology
@kuraoncology
1K Followers
Eisai Inc. is a research-based human health care (hhc) company breaking through in oncology and neurology. View our community guidelines: https://t.co/1XdB1FV47s
Eisai US
@EisaiUS
6K Followers
TG is a biotechnology company focused on the acquisition, development & commercialization of treatments for B-cell diseases.
TG Therapeutics
@TGTherapeutics
3K Followers
Iovance Biotherapeutics is dedicated to the fight against cancer.
Iovance Biotherapeuti...
@IovanceBio
2K Followers
Advancing novel medicines to empower the everyday lives of people living with hereditary angioedema (HAE).
KalVista Pharmaceutic...
@KalVista
612 Followers
Developing a novel class of therapeutic biologics to selectively engage and modulate disease-relevant T cells for the treatment of autoimmune disease
Cue Biopharma
@CueBiopharma
653 Followers
Oramed Pharmaceuticals (NASDAQ: ORMP) has developed an innovative technology to transform injectable treatments into oral therapies.
Oramed Pharma
@OramedPharma
2K Followers
Driving the next generation of endocrinology care. See our social community guidelines: https://t.co/ncgkUbzCVF
Crinetics Pharmaceuti...
@Crinetics
1K Followers
Project Lyme’s mission is to eradicate the epidemic of tick-borne diseases through awareness and education, support of cutting-edge science, and advocacy.
Project Lyme
@ProjectLyme
10K Followers
We're focused on the development & commercialization of therapeutics for people living with kidney disease. Guidelines: https://t.co/ReCXCqibZP
Akebia Therapeutics
@akebiatx
2K Followers
MeiraGTx is committed to the development of novel genetic medicines to transform the lives of patients suffering from acquired and inherited disorders.
MeiraGTx
@MeiraGTx
1K Followers
Delivering High Impact Medicines for Rare Disease
Mirum Pharmaceuticals
@mirumpharma
667 Followers